Bevacizumab and Lomustine for Recurrent GBM

NCT01290939 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

592

Enrollment

NETWORK

Sponsor class

Conditions

Glioblastoma Multiforme
Cognition Disorders
Disability Evaluation

Interventions

BIOLOGICAL: bevacizumab
DRUG: lomustine
GENETIC: DNA methylation analysis
OTHER: laboratory biomarker analysis
PROCEDURE: cognitive assessment
PROCEDURE: quality-of-life assessment

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]